Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16Genitourinary 10Head & Neck 5Gastrointestinal 5Thoracic 4Plasma cell 4Other 4Lymphoid 4Gynecologic 3Dermatologic 3Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other neoplasm 1Myeloid 1Classical hematology 1CNS 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sugars × Tumor-Agnostic × Clear all
NCT01238120 2021-05-05

The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients

University of Rochester

Phase 2 Completed
110 enrolled 15 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡